The pharmaceutical industry is moving past the hype phase of artificial intelligence and confronting what it actually takes to put the technology to work in drug discovery.
A cluster of market analyses signals fast growth. According to reports published via openPR.com, the market for AI in drug discovery and development is expanding, with one projection putting the AI-enabled drug discovery market on track to reach roughly USD 33,951.6 million.
There are concrete milestones behind the forecasts. According to Genetic Engineering and Biotechnology News, in a StockWatch column, AI-focused biotech Insilico is projecting profit and reported leaping revenue as its AI-developed lead candidate advances into Phase III trials — a late and demanding stage of human testing that few AI-originated drugs have reached.
Not every source is uniformly upbeat. A piece from 36Kr, headlined "Two Sets of Books for AI-Driven Pharmaceutical Research and Development," points to the gap between the promise of AI-driven R&D and the messier realities of implementing it — a reminder that ambitious projections and day-to-day results do not always line up.
Taken together, the coverage sketches an industry at an inflection point: bullish on AI's long-term market size, encouraged by a candidate reaching Phase III, but increasingly focused on the practical challenges of implementation rather than the promise alone.
Why it matters: if AI can reliably speed the discovery of new medicines and carry candidates through late-stage trials, it could reshape how quickly and cheaply new treatments reach patients — but only if the industry closes the gap between forecast and delivery.